Accropeutics has developed a robust portfolio of innovative compounds spanning from lead optimization to clinical trials. AC-101, a selective RIPK2 inhibitor, has completed Phase I clinical trials in Australia and China demonstrating an outstanding safety and PK/PD profile, and is currently undergoing a Phase Ib trial for Ulcerative Colitis (UC). AC-201, a selective TYK2/JAK1 inhibitor with "Pipeline-in-a-Product" potential for treating inflammatory and autoimmune diseases, has completed Phase I study in Australia and China, and The phase II clinical trial for patients with moderate to severe plaque psoriasis in China is about to be completed. AC-003, a selective RIPK1 inhibitor, has completed Phase I clinical trials in China and the United States as of August 2023 and achieved positive results, and is currently undergoing a Phase Ib clinical trial in aGVHD. The Company has multiple compounds in the PCC and preclinical research stages. The Company owns global rights of all its assets with more than 20 patents issued in major markets including the US, the EU, China, Japan, and Korea.
Dr. Henri Nico Doods was Senior Vice President of Boehringer Ingelheim and Global Head of Boehringer Ingelheim Research Beyond Border.
Dr. Doods has nearly 30 years of experience in pharmaceutical research and development, covering cardiovascular, pain, obesity, neurological, respiratory and other fields. He published more than 135 papers, and advanced more than 15 compounds into clinical development, including nintedanib (Ofev), the standard of care for the treatment of IPF. He received a Ph.D. degree is from University of Amsterdam.
Series B+ Financing
AC-101 First in Patient in Phase Ib for UC in China
AC-101 MRCT Phase II for UC was Approved by FDA
AC-201 Phase II clinical trial for NIU was approved by NMPA
AC-201 First in Patient in China for Phase II in Psoriasis
AC-003 First in Patient in China for Phase Ib in aGVHD
AC-101 clinical trial was approved (HREC)
AC-101 first in human in AUS
AC-003 clinical trial for GVHD was approved (NMPA)
AC-101 IND Approval (NMPA)
AC-201 first in human in AUS
AC-201 IND Approval (NMPA)
AC-201 first in human in China
AC-003 has been granted ODD by the FDA
AC-003 first in human in the US
AC-003 IND Approval (NMPA)
AC-003 first in human in China
Series B Financing
AC-003 IND Approval (FDA)
Series A Financing
Found Accro Bioscience (Suzhou) Limited
For investor relations related matters, please contact us at info@accropeutics.com
